X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs AJANTA PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA AJANTA PHARMA GSK PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 59.9 20.7 289.6% View Chart
P/BV x 11.7 8.9 131.4% View Chart
Dividend Yield % 2.1 0.7 312.8%  

Financials

 GSK PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
AJANTA PHARMA
Mar-16
GSK PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,8501,720 223.8%   
Low Rs2,9661,103 268.9%   
Sales per share (Unadj.) Rs332.3194.6 170.8%  
Earnings per share (Unadj.) Rs44.345.2 98.0%  
Cash flow per share (Unadj.) Rs47.250.3 93.9%  
Dividends per share (Unadj.) Rs50.008.00 625.0%  
Dividend yield (eoy) %1.50.6 258.9%  
Book value per share (Unadj.) Rs202.7132.0 153.5%  
Shares outstanding (eoy) m84.7088.77 95.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.37.3 141.4%   
Avg P/E ratio x76.931.2 246.5%  
P/CF ratio (eoy) x72.228.1 257.1%  
Price / Book Value ratio x16.810.7 157.2%  
Dividend payout %112.917.7 638.0%   
Avg Mkt Cap Rs m288,643125,299 230.4%   
No. of employees `0004.6NA-   
Total wages/salary Rs m4,4342,570 172.5%   
Avg. sales/employee Rs Th6,104.5NM-  
Avg. wages/employee Rs Th961.6NM-  
Avg. net profit/employee Rs Th813.7NM-  
INCOME DATA
Net Sales Rs m28,14817,275 162.9%  
Other income Rs m1,218166 732.6%   
Total revenues Rs m29,36617,442 168.4%   
Gross profit Rs m4,7745,807 82.2%  
Depreciation Rs m248451 55.0%   
Interest Rs m049 0.0%   
Profit before tax Rs m5,7445,474 104.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m260-   
Tax Rs m2,0181,460 138.2%   
Profit after tax Rs m3,7524,014 93.5%  
Gross profit margin %17.033.6 50.5%  
Effective tax rate %35.126.7 131.7%   
Net profit margin %13.323.2 57.4%  
BALANCE SHEET DATA
Current assets Rs m21,4627,639 281.0%   
Current liabilities Rs m10,5362,715 388.1%   
Net working cap to sales %38.828.5 136.2%  
Current ratio x2.02.8 72.4%  
Inventory Days Days6843 156.5%  
Debtors Days Days1679 20.9%  
Net fixed assets Rs m4,7176,914 68.2%   
Share capital Rs m847177 478.8%   
"Free" reserves Rs m16,30811,442 142.5%   
Net worth Rs m17,17111,721 146.5%   
Long term debt Rs m16149 10.8%   
Total assets Rs m30,62014,814 206.7%  
Interest coverage xNM112.9-  
Debt to equity ratio x00 7.3%  
Sales to assets ratio x0.91.2 78.8%   
Return on assets %12.327.4 44.7%  
Return on equity %21.934.2 63.8%  
Return on capital %33.646.5 72.1%  
Exports to sales %055.1 0.0%   
Imports to sales %15.16.0 250.6%   
Exports (fob) Rs m49,527 0.0%   
Imports (cif) Rs m4,2371,038 408.3%   
Fx inflow Rs m51910,422 5.0%   
Fx outflow Rs m8,3201,678 495.8%   
Net fx Rs m-7,8018,744 -89.2%   
CASH FLOW
From Operations Rs m1,3863,264 42.5%  
From Investments Rs m5,010-2,093 -239.4%  
From Financial Activity Rs m-6,383-1,186 538.4%  
Net Cashflow Rs m12-15 -79.7%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 1.6 658.1%  
FIIs % 23.8 7.6 313.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.0 90.6%  
Shareholders   102,036 20,968 486.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - STERLING BIOTECH COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS